Key result
Jervell and Lange-Nielsen syndrome has an estimated prevalence of at least 1:200,000 in Norway, driven by genetic homogeneity, mutational heterogeneity, and a founder mutation.
Answers are grounded in this paper and cite their sources.
This review highlights the unusually high prevalence of Jervell and Lange-Nielsen syndrome in Norway and outlines the genetic basis and clinical implications for screening and monitoring.
Jervell and Lange-Nielsen syndrome (MIM 220400; JLNS), is a rare form of profound congenital deafness combined with syncopal attacks and sudden death due to prolonged QTc; it is an autosomal recessive trait. After its first description in Norway in 1957, later reports from many other countries have confirmed its occurrence. Nowhere is the prevalence so high as in Norway, where we estimate a prevalence of at least 1:200,000. The KCNQ1 and KCNE1 proteins coassemble in a potassium channel, and mutations in either the KCNQ1 gene or the KCNE1 gene disrupt endolymph production in the stria vascularis in the cochlea, causing deafness. KCNQ1 seems to be the major gene in JLNS. Long QT syndrome (LQTS) is a separate disorder of either autosomal dominant or recessive inheritance caused by mutations in four different ion channel genes; KCNQ1 is the one most frequently involved. Some heterozygous carriers of JLNS mutations in either gene may suffer from prolonged QTc and be symptomatic LQTS patients with a need for appropriate medical treatment to prevent life-threatening cardiac arrhythmia. In general, frameshift/stop mutations cause JLNS, and missense/splice site mutations cause LQTS, but a precise genotype-phenotype correlation in LQTS and JLNS is not established, which complicates both genetic counseling and clinical risk evaluation in carriers. We review JLNS from a Norwegian perspective because of the unusually high prevalence, the genetic homogeneity associated with considerable mutational heterogeneity, and some evidence for recurrent mutational events as well as one founder mutation. We outline the clinical implications for investigation of deaf children and cases of sudden infant death syndrome as well as careful electrocardiographic monitoring of identified mutation carriers to prevent sudden death. Am. J. Med. Genet. (Semin. Med. Genet.) 89:137-146, 1999.
No takes yet. Share an insight, caveat, or question.
Tranebj�rg et al. (1999) conducted a review in Jervell and Lange-Nielsen syndrome. Jervell and Lange-Nielsen syndrome has an estimated prevalence of at least 1:200,000 in Norway, driven by genetic homogeneity, mutational heterogeneity, and a founder mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: